NCT01556009 - Trial Comparing the Effects of Intermittent Vismodegib vs. PDT in Patients With Multiple Basal Cell Carcinomas | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions

Basal Cell Nevus SyndromeGorlin's Syndrome

Interventions

DRUG

Vismodegib

150 mg per day for 7 continuous months then randomized for 3 month intervals to 28 months.

DRUG

Aminolevulinic acid %20 topical solution

20% topical solution applied every three months from month 10, 13, 16, 19, 22. Applied and incubated for three hours.

Trial Locations (3)

Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, New York

Children's Hospital Oakland Research Institiute, Oakland

Children's Hospital Research Center Oakland, Oakland